The Efficacy and Safety of 3% Cannabidiol (CBD) Cream in Patients With Epidermolysis Bullosa: A Phase II/III Trial

Related Clinical Trial
Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Epidermolysis Bullosa (Phase III, Cross-over) Growth Hormone in EB Dose-ranging Study of Dentoxol® Mouthrinse for Managing Oral Symptoms in People With Epidermolysis Bullosa. Study to Evaluate Safety and Efficacy of ALLO-ASC-SHEET in Subjects With Dystrophic Epidermolysis Bullosa Extension Study to PTR-01-002 Long-Term Follow-up Protocol A Long-term Treatment With B-VEC for Dystrophic Epidermolysis Bullosa Improve Adherence to Weak or Strong Opioid Analgesics at the Time of Care in Children With Hereditary Epidermolysis Bullosa Gynecological Follow-up of Patients With Dystrophic Epidermolysis Bullosa (EBD) Topical Gentamicin Nonsense Suppression Therapy of EB The Efficacy and Safety of 3% Cannabidiol (CBD) Cream in Patients With Epidermolysis Bullosa: A Phase II/III Trial A Study of PTR-01 in Recessive Dystrophic Epidermolysis Bullosa Safety and Effectiveness Study of Allogeneic Umbilical Cord Blood-derived Mesenchymal Stem Cell in Patients With RDEB The Objective of This Study is to Compare the Efficacy and Safety of Beremagene Geperpavec (B-VEC) Topical Gel With That of Placebo for the Treatment of Dystrophic Epidermolysis Bullosa (DEB). Trial To Assess Efficacy Of A Chimeric Skin In Patients With Epidermolysys Bullosa Randomised Double Blind Placebo Controlled Cross Over Design of the Efficacy of Topical Morphine for Inflammatory Pain in Children With Epidermolysis Bullosa Study of Cellutome System for Treatment of Individual Lesions in EB Pts Neurokinin-1 Receptor Antagonist for the Treatment of Itch in EB Patients A Neurokinin-1 Receptor Antagonist for the Treatment of Pruritus in Patients With Epidermolysis Bullosa Biochemical Correction of Severe EB by Allo HSCT and “Off-the-shelf” MSCs Survey to Identify Burdens and Unmet Needs of Patients With Epidermolysis Bullosa Study of the Nutritional, Metabolic, and Body Composition Profile in Children and Adolescents With Epidermolysis Bullosa MT2015-20: Biochemical Correction of Severe EB by Allo HSCT and Serial Donor MSCs Randomised Double Blind Crossover Placebo Controlled Study to Evaluate the Efficacy of Tetracycline in Epidermolysis Bullosa Observational Study of a Cohort of Patients With Hereditary Epidermolysis Bullosa Phase III Efficacy and Safety Study of Oleogel-S10 in Epidermolysis Bullosa A Observational Study to Evaluate Apligraf(R) in Nonhealing Wounds of Subjects With Epidermolysis Bullosa Study of Effectiveness and Safety of SD-101 in Participants With Epidermolysis Bullosa Open Label Extension Study to Evaluate the Long-term Safety of Zorblisa (SD-101-6.0) in Patients With Epidermolysis Bullosa Open-Label Extension Study to Evaluate the Safety of SD-101 Cream in Participants With Epidermolysis Bullosa ESSENCE Study: Efficacy and Safety of SD-101 Cream in Participants With Epidermolysis Bullosa Grafting of Epidermolysis Bullosa Wounds Using Cultured Revertant Autologous Keratinocytes Topical BPM31510 3.0% Cream in Patients With Epidermolysis Bullosa Evaluation of the Efficacy of ROPIVACAINE in Children and Young Adults With Hereditary Epidermolysis Bullosa Oleogel-S10 in Wound Healing of Inherited Epidermolysis Bullosa (BEB-10) The Efficacy of Trimethoprim in Wound Healing of Patients With Epidermolysis Bullosa A Phase 2 Study on Effect of Thymosin Beta 4 on Wound Healing in Patients With Epidermolysis Bullosa A Follow-up Study to Evaluate the Efficacy and Safety of ALLO-ASC-DFU in ALLO-ASC-EB-101 Clinical Trial Proof of Concept Study for a Dressing Glove Pregabalin Treatment for RDEB Pain and Itch Study of Alwextin® Cream in Treating Epidermolysis Bullosa A Study of the Efficacy and Safety of ABH001 in the Treatment of Patients With Epidermolysis Bullosa Who Have Wounds That Are Not Healing Uses of Irradiated Human Amniotic Membrane in the Treatment of Dystrophic Epidermolysis Bullosa Patients Allogeneic ABCB5-positive Stem Cells for Treatment of Epidermolysis Bullosa A Comparative Study of the Healing of Chronic Ulcers of Recessive Epidermolysis Bullosa : Dressing vs Amniotic Membrane Topical QR-313 in Dominant Dystrophic Epidermolysis Bullosa (DDEB) or Recessive Dystrophic Epidermolysis Bullosa (RDEB) Due to Mutation(s) in Exon 73 of the COL7A1gene Rigosertib for RDEB-SCC Phase I Study of Isotretinoin in Patients With Recessive Dystrophic Epidermolysis Bullosa Short Term Observational Study in DEB Patients Gentamicin for RDEB Clinical Trial to Assess Safety and Efficacy of Autologous Cultured Epidermal Grafts Containing Epidermal Stem Cells Genetically Modified in Patients With RDEB. Gentamicin Therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB) Nonsense Mutation Patients Self-Assembled Skin Substitute for the Treatment of Epidermolysis Bullosa Allogeneic Stem Cell Transplantation (ALLOSCT) in Recessive Dystrophic Epidermolysis Bullosa (RDEB) Allogeneic Hematopoietic Stem Cell Transplant For Epidermolysis Bullosa Topical Beremagene Geperpavec (KB103) Gene Therapy to Restore Functional Collagen VII for the Treatment of Dystrophic Epidermolysis Bullosa A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa (RDEB) A Phase 1/2 Trial of PTR-01 in Adult Patients With Recessive Dystrophic Epidermolysis Bullosa (RDEB) Gene Transfer for Recessive Dystrophic Epidermolysis Bullosa Intravenous Gentamicin Therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB) Molecular Signatures of Cutaneous Squamous Cell Carcinoma During Recessive Dystrophic Epidermolysis Bullosa Treatment of Chronic and Non-Chronic Wounds in Patients With Recessive Dystrophic Epidermolysis Bullosa Using Helicoll Collagen Dressings Versus Standard of Care Phase 3, Open-label Clinical Trial of EB-101 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB) MSC EVs in Dystrophic Epidermolysis Bullosa Mesenchymal Stromal Cells in Adults With Recessive Dystrophic Epidermolysis Bullosa Prospective, Longitudinal Natural History Study in Dystrophic Epidermolysis Bullosa Recessive Dystrophic Epidermolysis Bullosa Screening for Possible Gene Transfer Study of Immune Tolerance and Capacity for Wound Healing of Patients With Recessive Dystrophic Epidermolysis Bullosa (RDEB) Rigosertib in Patients With Recessive Dystrophic Epidermolysis Bullosa Associated SCC Treatment of Epidermolysis Bullosa Dystrophica by Polyphenon E (Epigallocatechin 3 Gallate) Characteristics of Adult Patients With Recessive Dystrophic Epidermolysis Bullosa Efficacy of Granulocyte Colony Stimulating Factor (GCSF) In Patients With Dystrophic Epidermolysis Bullosa Characteristics of Patients With Recessive Dystrophic Epidermolysis Bullosa Study to Evaluate the Safety of ALLO-ASC-DFU in the Subjects With Dystrophic Epidermolysis Bullosa The Natural History of Wounds in Patients With Dystrophic Epidermolysis Bullosa (DEB) A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa A Pilot Study of HP802-247 in Dystrophic Epidermolysis Bullosa

Brief Title

The Efficacy and Safety of 3% Cannabidiol (CBD) Cream in Patients With Epidermolysis Bullosa: A Phase II/III Trial

Official Title

The Efficacy and Safety of 3% Cannabidiol (CBD) Cream in Patients With Epidermolysis Bullosa: A Phase II/III Trial

Brief Summary

      Epidermolysis bullosa (EB) is rare, devastating, and currently incurable genetic blistering
      disorders characterized by fragility of skin and mucosal membranes. Therapeutic options for
      EB are limited. Acute and chronic wounds cause pain, itching and infection, altering quality
      of life and impair wound healing. In absence of a cure, wound care is paramount to alleviate
      suffering.

      Anecdotal experience suggest that CBD application alleviates the pain and itching and
      improves wound healing by controlling the inflammatory process. We propose to undertake a
      phase II/III study exploring the safety, tolerability and efficacy of topical application of
      3% Cannabidiol cream (CBD) on acute and chronic wounds affecting patients with EB.

      We are doing this trial to determine safety and tolerability of topical CBD cream in a cohort
      of RDEB patients with chronic wounds (phase II trial), and to evaluate the efficacy and
      safety of CBD cream in EB with acute and chronic wounds in promoting wound healing, decrease
      blister formation, pain, itching and improve overall quality of life (phase III trial)
    

Detailed Description

      Phase II is an open-label part of the study. We are planning to enroll in this phase 10
      patients, diagnosed with Epidermolysis Bullosa with chronic wounds , and treat them with
      topical application of 3% Cannabidiol cream (AVCN583601) for 4 weeks.

      Full study procedures (phase II of the trial), see below:

      Visit 1: Screening Visit: A screening form will be completed and patients who are willing to
      enroll and meet the eligibility criteria will be asked to sign the consent/assent form .
      Patients already on cannabinoids will be instructed to discontinue their treatment two weeks
      prior to the next visit (wash-out period). Subjects who were not treated with antibiotics or
      corticosteroids in the previous 2 weeks for topical and 4 weeks for systemic agents will
      start the trial at this time.

      Visit 2: Baseline Visit: A baseline data collection form will be completed. We will select
      for the study treatment a chronic wound (present for more than 4 weeks), not measuring more
      than 1000 cm2. The surface area of the wound and quality of the wounds will be assessed and
      documented using the SWIFT medical wound assessment app, a validated tool that allows serial
      estimates and measurements of the wound surface areas. Bacterial swabs of selected target
      wound and medical photographs of the target wounds will be taken. For the pain intensity
      assessment, we will use a 100 mm visual analog scale (VAS), where 0 is no pain and 10- the
      worst pain ever experienced, while the DN4 scale will be used for assessment of neuropathic
      pain. For itch assessments, we will ask patients to determine the degree of itching
      experienced that day using a 100 mm horizontal VAS for itch. Patients will be provided with
      the study medication during this study visit and instructed to apply the cream twice a day
      for 4 weeks.

      Blood sample (3 ml) will be taken to measure cannabinoid level in the blood. Visit 3: End of
      study visit: Patients will be assessed at 4 weeks when we will evaluate tolerability of the
      CBD oil and safety (e.g. burning sensation, pain, itch, local irritation, systemic symptoms).
      In addition, we will calculate the surface area change from previous visit as well as the
      characteristics of the wounds using the SWIFT medical wound assessment app. Patients will
      also be asked to score the average pain (VAS and DN4) and itching at the wound site for the
      prior 2 weeks and to complete a 100 mm VAS of wound change where -100 is the wound is double
      in size, 0- no change, and +100, wound is completely closed. Medical photographs of the
      target wounds will be taken.

      Blood sample (3 ml) will be taken to measure cannabinoid level.

      The study participants, completed phase II , who are willing to take part in phase III, will
      be able to participate , if eligible ( after appropriate wash out period).

      Phase III will be a randomized, placebo controlled, blinded study ( Right versus Left side
      extremity), assessing the efficacy and safety CBD cream in EB patients with acute and chronic
      wounds.

      30 EB patients with chronic or/and acute wounds, will participate in phase III. Randomization
      and Blinding: The name of each patient will be submitted to the research pharmacist. He will
      prepare a randomization scheme and will allocate patients' extremity to either placebo or CBD
      cream. Families and patients, as well as investigators will be blinded to the type of
      intervention throughout the duration of the study.

      The intervention is CBD 3% cream / placebo. The study medications will be dispensed as 100 g
      jars. The study treatment will be applied to the entire or selected area of the extremity
      twice a day for 8 weeks (a drawing will be provided to the patients and to the assessors for
      the purpose of consistency).

      The "placebo" will consist of a cream formulation with same color, consistency and smell as
      the intervention which will be applied on the other extremity (the application will mirror
      the process for the active medication).

      Both jars will be labeled appropriately with the location and dosage instructions.

      Allowable therapies: Patients will continue the same skin care routine and dressings with the
      exceptions of use of topical corticosteroids and topical antibiotics. Dressings that are
      impregnated with antimicrobials (silver, PHMB, honey, etc) are allowed if previously used.

      Procedures: For the purpose of this phase we will select 2 different patient populations: A:
      acute wounds group (wounds that have been present for less than 4 weeks; B: chronic wounds
      group (wounds that have been present for >4 weeks) seen in patients with more severe types of
      EB.

      For patients who have more than one chronic wound in the selected extremity we will add the
      individual wounds' surface areas.

      Visit 1: Screening Visit: A screening form will be completed and patients who are willing to
      enroll and meet the inclusion criteria will be asked to sign the consent/assent form by our
      study nurse. Patients already on topical or systemic cannabinoids will be instructed to
      discontinue their treatment two weeks prior to the next visit (Wash-out period).

      Visit 2: Baseline Visit:

      In addition to the demographic and clinical, disease specific characteristics we will collect
      the following data:

      Blister count, open and closed wound count, evidence of infection, dyspigmentation, EB nevi.

      For patients with chronic wounds: surface area, wound characteristics , wound swab for
      culture and sensitivity, Current wound care regimen Pain score (VAS and DN4) Itch score
      iscorEB (clinician and patient) EBQOL CBD level (blood sample 3 ml)

      Visit 3: Mid study visit (4 weeks): We will collect the same information as for baseline
      visit (Visit 2) and additional data:

      VAS improvement patient Adverse events

      Visit 4: End of study visit (8 weeks): We will collect the same information as for previous
      visit (Visit 3) , plus - the CBD level in the blood will be measured again ( 3 ml sample).

      Wound swab will be taken ( group B), if the study investigator deems it is necessary.
    

Study Phase

Phase 2/Phase 3

Study Type

Interventional


Primary Outcome

Group A (patients with acute wounds). Difference in the total wound count (blister, open and closed wounds) compared to baseline

Secondary Outcome

 • Percentage of patients that needed to stop the medication as a result of an adverse event

Condition

Epidermolysis Bullosa

Intervention

AVCN583601 (3% Cannabidiol cream)

Study Arms / Comparison Groups

 interventional arm, phase 2
Description:  All participant of phase 2 will receive CBD cream for their chronic wound treatment.
This is an open-label part of the study.

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Drug

Estimated Enrollment

0

Start Date

August 1, 2020

Completion Date

December 30, 2022

Primary Completion Date

September 1, 2022

Eligibility Criteria

        Inclusion Criteria:(phase 2) Patients 4-50 years of age

          -  Diagnosis of RDEB (clinically and/or molecular diagnosis)-

          -  Wounds that have not been healing for over 4 weeks

          -  Signed consent/assent form Inclusion criteria -Phase 3

          -  Patients 4-50 years of age

          -  Diagnosis of EB (clinically and/or molecular diagnosis)

          -  Evidence of either acute or chronic wounds on both extremities

          -  Patients enrolled in phase II are also eligible for participation in this phase, if
             they meet the current criteria and are interested in participation * Signed
             consent/assent form

        Exclusion Criteria:

          -  Previous known allergy or intolerance to CBD cream

               -  Topical and systemic use of cannabinoids in the past 2 weeks

               -  Topical use of antibiotics, corticosteroids for the past 2 weeks

               -  Other systemic medications that will interfere with the wound healing
                  (corticosteroids, immunosuppressives, antibiotics) in the past 4 weeks

               -  Surgery of the selected area in the past 8 weeks

               -  Patients received medications metabolized via CYP3A4 enzyme (ketoconazole,
                  itraconazole, ritonavir, clarithromycin, phenobarbital, rifampicin,
                  carbamazepine, hexobarbital) for the past 2 weeks

               -  Pregnancy
      

Gender

All

Ages

4 Years - 50 Years

Accepts Healthy Volunteers

No

Contacts

Elena Pope, MD, , 

Location Countries

Canada

Location Countries

Canada

Administrative Informations


NCT ID

NCT04613102

Organization ID

1000062062


Responsible Party

Sponsor-Investigator

Study Sponsor

Elena Pope

Collaborators

 Avicanna Inc

Study Sponsor

Elena Pope, MD, Principal Investigator, The Hospital for Sick Children


Verification Date

June 2021